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1. Introduction 
Cancer pain treatment is based on the analgesic ladder, established in 1986 by the World 
Health Organization (WHO; see Fig. 1) (WHO, 1996). Cancer pain management guidelines 
in Europe are based on EAPC (European Association for Palliative Care) recommendations. 
Oral morphine is recommended by the Expert Working Group of the EAPC at the third step 
of the WHO analgesic ladder, which comprises additional opioids (i.e. oxycodone, fentanyl, 
buprenorphine, methadone, and hydromorphone) for the treatment of moderate-to-severe 
pain intensity (Hanks et al., 2001). The use of an analgesic ladder should be individualized 
with an appropriate application of supportive drugs (laxatives and antiemetics) for the 
prevention and treatment of opioid adverse effects (Leppert, 2009a) and 
nonpharmacological measures, such as radiotherapy and invasive procedures (nerve 
blockades and neurolytic blocks) (Eidelman et al., 2007). 
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Fig. 1. World Health Organization three-step analgesic ladder 
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Each step of the WHO analgesic ladder: nonopioids (analgesics for mild pain, step 1 
analgesics), weak opioids (analgesics for mild to moderate pain, step 2 opioid analgesics), 
and strong opioids (opioids for moderate-to-severe pain intensity, step 3 opioid analgesics) 
may be accompanied with adjuvant analgesics (coanalgesics), which can enhance opioid 
analgesia. In patients with bone pain, opioids may be combined with non-steroidal anti-
inflammatory drugs (NSAIDs), glucocorticoids, and bisphosphonates along with local or 
systemic radiotherapy (Lussier et al., 2004). In patients with very severe neuropathic pain, a 
combination of opioids and NMDA (N-methyl D-aspartate)-receptor antagonists (e.g. 
ketamine) are recommended (Leppert, 2010a). Patients with neuropathic pain along with 
opioids may also receive anticonvulsants, and antidepressants (Bennett, 2011). Other drug 
groups used in patients with neuropathic pain component comprise local anesthetics and 
antiarrhytmics (Freynhagen & Bennett, 2009). Opioid analgesics should be supplemented 
with spasmolytics in patients with visceral colicky pain, especially in the course of bowel 
obstruction (Ripamonti et al., 2008). 
2. Opioids for mild to moderate pain (weak opioids, step 2 opioid analgesics) 
2.1 Tramadol 
Tramadol displays opioid properties and acts on neurotransmission of noradrenalin and 
serotonin. Both enantiomers act synergistically and improve analgesia without increasing 
adverse effects. Tramadol is metabolized in the liver and excreted by the kidneys. The main 
metabolite is O-desmethyltramadol (M1), which displays analgesic activity with a higher 
affinity to μ-opioid receptors than the parent compound; (+)-M1 has 300 to 400 times greater 
affinity to μ-opioid receptors than tramadol and (-)-M1 mainly inhibits noradrenalin 
reuptake. Apart from O,N-didesmethyltramadol (M5, which has weak analgesic activity) 
and M1, other metabolites are inactive (Leppert and Mikolajczak, 2011). The elimination 
half-life of tramadol is 5 to 6 hours and that if M1 is 8 hours. During oral administration, 
90% of tramadol is excreted by the kidneys and 10% in feces. Patients with renal impairment 
show a decreased excretion of tramadol and M1. In patients with advanced cirrhosis, there 
is a decrease in tramadol metabolism with decrease of hepatic clearance and increase in 
blood serum levels. In these patients, elimination half-life is increased 2.5-fold. The starting 
dose of immediate-release (IR) tramadol is 25 to 50 mg every 4 to 6 hour and that of 
controlled-release (CR) tablets or capsules is 50 to 100 mg twice daily; the daily dose should 
not exceed 400 mg (Dickman, 2007). 
Patients devoid of CYP2D6 activity (poor metabolizers) need a tramadol dose higher by 30% 
than those with normal CYP2D6 activity (extensive metabolizers) (Stamer et al., 2003). 
Tramadol analgesia depends on CYP2D6 genotype, with less analgesia in poor metabolizers 
being associated with lack of (+)-M1 formation (Stamer et al., 2007). Genotyping is helpful in 
patients with duplication of CYP2D6 gene (ultrarapid metabolizers [UM]) who are at greater 
risk to develop tramadol adverse effects. Tramadol metabolism through CYP2D6 may cause 
interactions with drugs inhibiting this enzyme (eg, cimetidine and ranitidine). 
Serotonin syndrome has been reported in patients taking selective serotonin reuptake 
inhibitors (SSRIs) in conjunction with tramadol or opioids (Gnanadesigan et al., 2005). SSRIs 
(eg, fluoxetine, paroxetine, and, to less extent, sertraline) used in conjunction with tramadol 
may cause serotonin syndrome because SSRIs inhibit tramadol metabolism and increase 
serotonin level; generally, they should not be coadministered with tramadol. Serotonin 
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syndrome may appear with monoamine oxidase (MAO) inhibitors, olanzapine, risperidone, 
venlafaxine and mirtazapine (Davies and Glare, 2009).  
The inhibition of tramadol metabolism to (+)M1 may attenuate tramadol analgesia.  
For example, coadministration of ondansetron (selective 5-HT3 [hydroxytryptamine] 
receptor antagonist) blocks spinal 5-HT3 receptors and competitively inhibits CYP2D6 
although recent studies did not confirm such interaction (Rauers et al., 2010). Tramadol 
analgesia also may be impaired by coadministration of carbamazepine, which accelerates 
tramadol and M1 metabolism. Concomitant administration of tricyclic antidepressants 
increases the risk of seizures. Tramadol should be avoided in patients with history of 
epilepsy. In rats and mice, concomitant administration of tramadol and β-blocker and the 5-
HT1A/1B antagonist pindolol enhances analgesia (Leppert, 2009b). 
Respiratory depression is rare in the chronic use of tramadol. When it does occur, 
respiratory depression is connected with the opioid mode of tramadol action, so naloxone 
should be administered. For example, respiratory depression was reported in a cancer 
patient with renal impairment (creatinine clearance 30 mL/min) and with UM genotype 
after renal carcinoma resection. As respiratory symptoms appeared more than 10 hours after 
the first tramadol dose, the accumulation of M1 was the cause. The patient recovered after 
intravenous (IV) naloxone bolus administration (0.4 mg). This case highlights that tramadol 
should not be prescribed in patients with UM genotype and renal impairment (Stamer et al., 
2008).  
2.2 Codeine 
Codeine is a methylated morphine derivative that is found naturally, along with morphine, 
in the poppy seed. Codeine displays analgesic and antitussive activity. Codeine is available 
as IR and CR formulations but also in the form of paracetamol combined preparations. IR 
codeine is administered every 4-6 h in chronic pain with a starting single dose of about  
30 mg. The daily doses of dihydrocodeine and codeine usually do not exceed 240 mg and 
300 mg, respectively; when these analgesics are ineffective, opioids for moderate-to-severe 
pain (strong opioids) are introduced. 
Codeine is metabolized in the liver and its bioavailability is 30% to 40% after oral 
administration. After oral administration of codeine, maximal plasma concentration is 
attained within 1 to 2 hours with plasma half-life of 2.5 to 3.5 hours and analgesia 
maintained for 4 to 6 hours (IR formulations). Codeine is partially metabolized to morphine 
and its metabolites and to codeine metabolites norcodeine (NORC) and codeine-6-
glucuronide (C-6-G) (Lötsch et al., 2006). The analgesic effect of codeine is about equal to 
1/10th of morphine analgesia. Polymorphism of CYP2D6 is responsible for the formation of 
morphine, and its metabolites may affect codeine analgesia. Other codeine metabolites, C-6-
G predominantly, also display analgesic activity and contribute to codeine analgesia (Vree  
et al., 2000). In healthy volunteers, codeine is metabolized to C-6-G (81.0% ± 9.3%), NORC 
(2.16% ± 1.44%), morphine (0.50% ± 0.39%), morphine-3-glucuronide (M-3-G; 2.10% ± 
1.24%), morphine-6-glucuronide (M-6-G; 0.80% ± 0.63%), and normorphine (NORM; 2.44% ± 
2.42%). The half-life of codeine is 1.47 hours ± 0.32 hours, and that of C-6-G is 2.75 hours ± 
0.79 hours. The plasma AUC of C-6-G is about tenfold higher than that of codeine. Protein 
binding of codeine and C-6-G in vivo is 56.1% ± 2.5% and 34.0% ± 3.6%, respectively (Vree & 
Verwey-van Wissen, 1992). 
Lötsch et al. explored the contributions from codeine and its metabolites to central nervous 
analgesic effects independent from O-demethylation of codeine to morphine. A 
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pharmacokinetic/pharmacodynamic fit of the miotic effects by use of morphine as the only 
active compound was most significantly (P < 0.0001) improved when C-6-G as a second 
active moiety was added. CYP2D6-dependent formation of morphine does not explain 
exclusively the central nervous effects of codeine, and C-6-G is the most likely additional 
active moiety with possible contribution of NORC and the parent compound (Lötsch et al., 
2006). 
Gasche et al. depicted a patient who received oral codeine in a daily dose of 75 mg (25 mg 
three times a day) and who, after 4 days of treatment, experienced respiratory depression. 
The patient recovered after IV administration of naloxone (0.4 mg). The cause of the 
symptoms was CYP2D6 UM phenotype. The patient was concomitantly treated with 
clarithromycin and voriconazole, both known inhibitors of CYP3A4. This together with 
CYP2D6 gene duplication led to increased morphine formation. Blood concentrations of M-
3-G and M-6-G were substantially elevated, also due to renal failure (Gasche et al., 2004). 
Recent reports (Kircheiner et al., 2007; Voronov et al., 2007) indicate that there is a significant 
risk of respiratory depression in infants whose mothers with CYP2D6 UM and 
UGT2B72/2 genotypes taking codeine during breastfeeding (Madadi et al., 2009b). 
Guidelines for maternal codeine use during breastfeeding were issued in Canada (Madadi et 
al., 2009a) but it seems safer not to use codeine and substitute it with other analgesics in this 
patient group. Apart from morphine glucuronides, codeine and its metabolites (C-6-G and 
NORC) also contribute to codeine analgesic effects (Lötsch et al., 2006). 
2.3 Dihydrocodeine 
Dihydrocodeine (DHC) is a semi synthetic analogue of codeine. Apart from analgesic and 
antitussive activity, DHC also is used in the treatment of opioid addiction. After 
subcutaneous (sc) administration of DHC, 30 mg, analgesia is similar to that induced by 
10 mg of morphine. After parenteral administration, DHC is twice as potent as codeine. 
Bioavailability of DHC after oral administration is 20%, which indicates that its analgesia 
after oral administration is slightly stronger than that of codeine (bioavailability after oral 
administration equals 30%–40%). After oral administration of DHC, the maximal serum 
concentration appears after 1.7 hours, plasma half-life varies 3.5 to 5.5 hours, and 
analgesia lasts 4-6 hours. DHC pharmacokinetics was assessed in 12 extensive 
metabolizers of CYP2D6 (Ammon et al., 1999). They received a single oral DHC dose of 60 
mg, then after 60 hours, they were treated for 3 days with 60 mg dosed twice daily; for the 
next 3 days with 90 mg twice daily; and for 3 subsequent days 120 mg twice daily. In the 
60 to 120 mg DHC dose range, pharmacokinetics of DHC and dihydromorphine (DHM) 
displayed linear characteristics: area under the curve (AUC), c max (maximum serum 
concentration), and cssmin (minimum serum concentration at steady state) for both 
compounds increased depending on the drug dose (Rowell et al., 1983). Even though 
DHM displays higher affinity (about 100-fold) to the µ-opioid receptors and exhibits 
higher analgesic activity in comparison to the parent compound, the role of DHM and its 
glucuronides in DHC analgesia has not been unequivocally established. The starting dose 
of IR DHC is usually 30 mg every 4 to 6 hours, and that of CR tablets is 60 mg twice daily 
(Leppert, 2010b). 
Renal clearance and the clearance to DHC metabolites, glucuronidation, and O-
demethylation to dihydrocodeine-6-glucuronide (DHC-6-G) and DHM, respectively, are not 
dose dependent, which indicates that metabolism and excretion of DHC and its metabolites 
are also not dose dependent. Moreover, the ratio of DHC to DHM for AUC does not change 
www.intechopen.com
 
The Role of Opioid Analgesics in the Treatment of Pain in Cancer Patients 
 
325 
depending on the dose, which suggests a lack of saturation effect of the O-demethylation 
process of DHC to DHM depending on CYP2D6 in patients normally metabolizing the 
substrates of this enzyme. Pharmacokinetic parameters were similar after single and 
multiple doses of 60 mg of DHC (Ammon et al., 1999). Single-dose and multiple-dose 
pharmacokinetics of IR and CR DHC formulations provide support for a twice-daily dosage 
schedule of CR DHC. DHC is metabolized in the liver to main metabolites: DHM, DHC-6-G, 
and nordihydrocodeine (NORDHC). NORDHC is further glucuronidated to NORDHC-6-
glucuronide and O-demethylated to nordihydromorphine (NDHM). DHM undergoes 
glucuronidation to dihydromorphine-3-glucuronide (DHM-3-G) and dihydromorphine-6-
glucuronide (DHM-6-G) and N-demethylation to NDHM. It may be concluded that DHC 
undergoes the first pass effect after oral administration, which is connected with the 
formation of significantly higher amount of metabolites after oral than after parenteral 
administration (Rowell et al., 1983). Studies performed to date (Schmidt et al., 2003; Webb et 
al., 2001) indicate that DHC analgesia is independent of CYP2D6 activity (Leppert and 
Majkowicz, 2010). 
3. Opioids for moderate to severe pain (strong opioids, step 3 opioid 
analgesics) 
3.1 Morphine 
Morphine is the standard drug for the treatment of moderate to severe cancer pain and is a 
comparator for other strong opioids (Caraceni et al., 2011). This is predominantly due to 
large clinical experience and different routes of morphine administration (eg, oral, SC, IV, 
intrathecal, topical). Morphine is a hydrophilic opioid and a pure opioid agonist that acts 
predominantly through the activation of µ-opioid receptors (Flemming, 2010). Plasma half-
life of IR formulations equals 2 to 3 hours and the bioavailability after oral morphine 
administration equals about 30% to 40%. Morphine undergoes glucuronidation; thus, there 
is little risk of pharmacokinetic interactions with other drugs. 
The active metabolite responsible for analgesia is morphine-6-glucuronide (M-6-G). The 
accumulation of morphine and M-6-G may cause nausea and vomiting, sedation, and 
finally, respiratory depression. Morphine-3-glucuronide (M-3-G) is devoid of analgesic 
properties but may be responsible for neurotoxic effects and opioid hyperalgesia 
(paradoxical pain) (Gretton & Riley, 2008). The main drawback of morphine is the fact that 
M-3-G and M-6-G may accumulate especially in patients with renal impairment and renal 
failure, leading to possible intense adverse effects associated with accumulation of 
metabolites. In severe pain syndromes a change from oral to parenteral or intrathecal route 
of morphine administration may be beneficial. In case of renal problems, a switch from 
morphine to other opioids, such as fentanyl, methadone, or buprenorphine, is 
recommended. Similar to other opioids, morphine often causes constipation; therefore, the 
use of laxative prophylaxis is recommended. Common morphine adverse effects and 
possible management possibilities are showed in Table 1. 
Numerous oral CR formulations of morphine, designed for 12-hour and 24-hour 
administration, were developed (Ridgway et al., 2010). Local administration of morphine 
prevents systemic adverse effects. The starting daily dose of oral morphine is usually 20 to 
30 mg (for opioid-naïve patients) or 40 to 60 mg (for patients unsuccessfully treated with 
weak opioids) (Ripamonti et al., 2009). The dose of parenteral (SC or IV) morphine is one 
third of the morphine oral dose (Donnelly et al., 2002).  
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Adverse effect Symptomatology Treatment Comments 
Gastric stasis 
Epigastric 
fullness, nausea 
Metoclopramide 10 mg 
t.i.d. 
If the symptom persists a 
switch to alternative opioid 
may be useful 
Nausea/vomit
ing induced by 
vestibular 
stimulation 
Symptoms appear 
on movement 
Promethazine or cyclizine 
25 mg t.i.d. 
If intractable consider 
levomepromazine 
Constipation 
Flatulence, 
abdominal pain 
painful bowel 
movements, 
Stool softener (macrogol 
or lactulose) plus 
stimulant (senna or 
bisacodyl). 
If no effect rectal 
measures or 
methylnaltrexone 
If no effect consider switch to 
transdermal fentanyl or 
transdermal buprenorphine 
Sedation Drowsiness 
Reduce dose of 
morphine, consider 
methylphedindate 5-10 
mg o.d.-b.d. 
May be caused by co-
administered medications 
e.g. neuroleptics, 
benzodiazepines, 
antidepressants and co 
morbidities (hepatic/renal 
failure). Consider opioid 
switch 
Neurotoxicity/ 
cognitive 
failure 
Hyperalgesia, 
allodynia, 
myoclonic 
jerks/agitation, 
hallucinations 
Reduce dose of 
morphine, haloperidol – 1 
– 2 mg b.d. or risperidone 
1 – 2 mg o.d.-b.d. 
If no improvement consider  
opioid switch 
Table 1. Common adverse effects of morphine and management possibilities 
3.2 Oxycodone 
Oral oxycodone is along with oral morphine recommended as a first choice opioid 
analgesic for the treatment of moderate to severe cancer-related pain (King et al., 2011). It 
is a semi synthetic thebaine derivative, a strong opioid that displays a significant affinity 
to κ-opioid receptors along with agonistic effect mediated by µ-opioid receptors. Limited 
cross-tolerance is observed between oxycodone and morphine in rats and in clinical 
studies (Maddocks et al, 1996). In comparison to morphine, oxycodone possesses lower 
affinity to µ-opioid receptors and similar lipid solubility. Oxycodone permeates the 
blood–brain barrier very quickly, which may explain its stronger analgesic effect in 
comparison to other opioids. Oxycodone does not display immunosuppressive effects in 
experimental studies. It has high oral bioavailability (60%–87%); the plasma half-life is 2 
to 3 hours after IV administration, 3 hours after treatment with IR oral solution, and 8 
hours after CR tablets. The bioavailability of rectal administration is similar to oral route 
(61%), but it displays greater variability. 
Oxycodone is metabolized in the liver primarily to noroxycodone through CYP3A4 and, 
to a much less extent, to oxymorphone via CYP2D6. Noroxycodone is metabolized to 
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noroxymorphone through CYP2D6, and oxymorphone is metabolized to 
noroxymorphone by CYP3A4. However, analgesia observed after oxycodone 
administration relies primarily on the parent compound. Noroxycodone has 17% of the 
potency of oxycodone. Oxymorphone, in spite of high affinity for µ-opioid receptors, is 
produced in very small amounts. Noroxymorphone is produced in a significant amount 
and displays significant affinity for opioid receptors. However, the blood–brain barrier is 
extremely impermeable to noroxymorphone; thus, its role in analgesia is negligible. Low 
blood–brain barrier permeability is also characteristic of noroxycodone and oxymorphone 
(Leppert, 2010c). 
In patients with liver cirrhosis and hepatic diseases, the oxycodone dose should be reduced 
by half. Oxycodone is excreted through the kidneys. In patients with renal insufficiency, the 
oxycodone dose also should be reduced. In patients with renal failure, the oxycodone half-
life is prolonged and ranges from 1.8 to 26 hours. The elimination of noroxycodone and 
oxymorphone also is impaired in patients with renal failure. CYP2D6 polymorphism 
probably does not influence oxycodone analgesia and adverse effects. Sertraline minimally 
inhibits CYP2D6 and intensifies adverse effects of oxycodone (eg, hallucinations, tremors), 
whereas fluoxetine and quinidine (significant CYP2D6 inhibitors) do not intensify 
oxycodone adverse effects. Oxycodone reduces oral bioavailability of cyclosporine by half. 
In healthy patients, rifampin, a CYP3A4 inducer, greatly decreased oral and IV oxycodone 
AUC by 86% and 53%, respectively (P < 0.001), and modestly reduced analgesia and 
increased plasma metabolite-to–parent compound ratios for noroxycodone and 
noroxymorphone (P < 0.001) (Nieminen et al., 2009). A pharmacodynamic interaction of 
oxycodone with other drugs acting on the central nervous system, such as benzodiazepines, 
neuroleptics, and antidepressants, may intensify oxycodone adverse effects, especially 
sedation, and respiratory depression may be intensified in the case of patients who are more 
sensitive to opioids. 
3.3 Hydromorphone 
Oral hydromorphone is an alternative to oral morphine and oral oxycodone as a first choice 
opioid analgesic for the treatment of moderate to severe cancer pain (Pigni et al, 2011). 
Hydromorphone has about 5 to 10 times more potent analgesic effect than morphine and 
similar pharmacodynamic properties. Hydromorphone analgesia is mainly due to µ-opioid–
receptor agonist effects; it also features some affinity for δ- but not for κ-opioid receptors 
(Murray & Hagen, 1995). After hydromorphone administration, analgesia lasts for about 4 
to 6 hours and the plasma half-life is about 2.5 hours; sustained-release oral preparations 
provide analgesia for 12-24 hours (Gardner-Nix & Mercadante, 2010). 
The drug is metabolized mainly to hydromorphone-3-glucuronide that is devoid of 
analgesic activity and may accumulate in patients with renal failure; it may induce 
neurotoxic adverse effects to larger extent than the respective morphine metabolite 
(morphine-3-glucuronide) (Wright et al., 2001). Hydromorphone in small amount is also 
metabolized to 6-hydroxy-hydromorphone, but its role is unknown. Due to glucuronidation, 
the risk of hydromorphone pharmacokinetic interactions with other drugs seems to be low 
(Sarhill et al., 2001). Adverse effects are similar to those of morphine; however, 
hydromorphone less frequently induces nausea and vomiting, constipation, itching, and 
probably more slowly develops tolerance to analgesia (Wirz et al., 2008). In comparative 
studies conducted in cancer patients with pain hydromorphone displays similar analgesic 
efficacy to morphine (Miller et al., 1999) and oxycodone (Hagen and Babul, 1997). 
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Hydromorphone is especially useful for patients requiring high opioid doses via parenteral 
route due to strong analgesic effects and increased solubility that enables the possibility 
administering small volumes of the drug in SC injections.  
3.4 Fentanyl 
Fentanyl is a lipophilic opioid, µ-opioid–receptor agonist, with analgesic effect about 100 
times more potent than that of morphine. In chronic pain treatment, transdermal fentanyl 
(TF) patches are applied, usually on the upper trunk. There are five types of patches that 
release 12, 25, 50, 75, and 100 µg/h equal to approximately 0.3, 0.6, 1.2, 1.8, and 2.4 mg 
fentanyl dose per day, respectively. Patches are changed every 72 hours. Patients need 
access to short-acting opioid preparations (i.e. oral or parenteral morphine, buccal fentanyl 
tablets, oral transmucosal fentanyl citrate [OTFC] or fentanyl spray) during TF therapy to 
effectively manage breakthrough pain episodes. Fentanyl is metabolized mainly to inactive 
norfentanyl; thus, it may be used in patients with renal impairment. Because the fentanyl 
metabolic pathway is through CYP3A4, the drugs inhibiting or inducing this enzyme should 
be avoided. Caution is recommended when using drugs metabolized via CYP3A4. In 
comparison to morphine, the advantages of TF include milder constipation, nausea, and 
drowsiness (Ahmedzai & Brooks, 1997). 
When starting TF in opioid-naive or strong opioid–naïve patients, one patch at a dose of 
12 and 25 µg/h is recommended, respectively. TF also may be used in opioid switch, 
especially in patients treated with morphine who suffer from intractable constipation. In 
an open-label study of 16 patients with cancer pain unable to take oral opioids, TF was 
effective and well tolerated (Leppert et al., 2000). A good analgesic effect was achieved in 
11 patients, with a partial effect in an additional 2 patients. TF was effective and well-
tolerated in patients formerly treated with weak opioids that did not provide satisfactory 
analgesia (Vielvoye-Kerkmeer et al., 2000). The indications for TF include patients’ 
preferences, intense constipation during morphine treatment, morphine intolerance, 
nausea, and vomiting. TF should not be used in patients with unstable pain syndromes, 
especially with neuropathic pain component due to the long plasma half-life (20 h) of the 
drug, which hinders quick and effective dose titration. Fentanyl may be successfully used 
by other routes (e.g. SC, IV, intranasal inhaled, buccal) in the treatment of breakthrough 
pain (Slatkin et al., 2008). 
3.5 Buprenorphine 
Buprenorphine is a partial µ-opioid–receptor agonist and κ-receptor antagonist. A ceiling 
analgesic effect may be obtained at high doses (ie, 15 mg); however, such high doses are not 
used in clinical practice. The analgesic potency of buprenorphine is about 100 times greater 
than oral morphine (Likar et al., 2008). Buprenorphine may be administered sublingually 
due to low oral bioavailability at doses 0.2 to 0.8 mg, usually 3 times daily. It also may be 
administered by parenteral route (SC or IV). 
Buprenorphine is metabolized to the active metabolite norbuprenorphine via CYP3A4. The 
parent compound and norbuprenorphine undergo glucuronidation; thus, the risk of 
pharmacokinetic interactions with other drugs is low. Compared with morphine, 
buprenorphine less frequently induces constipation, nausea, and vomiting, which is 
probably associated with higher lipophilicity. Buprenorphine is mainly excreted with feces 
(2/3) and 1/3 of the drug is excreted with urine therefore, it may be used in patients with 
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renal failure. Respiratory depression is rare; however, when the symptom appears, naloxone 
injection should be administered at a dose of 2 mg, followed by continuous infusion (4 
mg/h). Buprenorphine displays antihyperalgesic activity and may be successfully used in 
the treatment of neuropathic pain (Mercadante et al., 2007). 
Buprenorphine is administered in transdermal patches (TB) releasing 35, 52.5, and 70 g/h, 
which corresponds to 0.8, 1.2, and 1.6 mg/d, respectively. The patches are changed every 84 
to 96 hours. In some countries, patches releasing 5 and 10 g/h, changed weekly, are 
available. The starting dose for strong opioid–naïve patients is usually one patch of 35 g/h. 
However, opioid-naive patients and those with renal or hepatic impairment may start with 
a dose of 17.5 g/h. The treatment is usually well-tolerated. At doses up to 140 g/h, TB 
does not display ceiling analgesia (Kress, 2009). Breakthrough pain may be treated with 
sublingual buprenorphine tablets or with IR morphine administered by oral or parenteral 
route (Mercadante et al., 2006). 
3.6 Methadone 
Methadone is a synthetic opioid and a racemate of dextrorotatory (S-methadone) and 
levorotatory (D-methadone) isomers. Methadone activates μ, κ, and Δ receptors (D-
methadone); it displays moderate antagonistic effect to NMDA receptors (both enantiomers) 
and strongly inhibits the reuptake of serotonin and noradrenalin in the central nervous 
system (S-methadone). In high doses, methadone blocks potassium channels required for 
rapid cardiac muscle repolarization, which may explain the risk of developing ventricular 
arrhythmia. 
Methadone is administered mostly to patients with cancer pain who undergo opioid switch; 
usually methadone is given every 8 hours. In comparison to morphine, 10 times less 
demand for laxatives and 2 times less nausea and vomiting were observed. Methadone may 
be administered as the first strong opioid to patients who have been treated with opioids for 
moderate pain or to opioid-naïve patients (the starting dose is usually 3–5 mg every 8 h) 
(Ripamonti et al., 1998) although EAPC recommends methadone as the second or the third-
line opioid. Methadone can be administered to patients with renal impairment. It has weak 
immunosuppressive effect and does not suppress the functioning of natural killer cells. 
Methadone is tenfold less expensive than the CR morphine and 25-fold cheaper than TF. 
Methadone is a highly lipophilic and basic drug with a high distribution volume (4.1 ±  
0.65 L/kg) and a high affinity to tissues, where it cumulates after multiple administrations 
(in brain, lung, liver, gut, kidney, and muscles). The high affinity to tissues together with a 
gradual, retarded release to plasma is the cause of a prolonged half-life. The bioavailability 
of the drug after oral administration oscillates between 70% and 90%. The half-life is about 
24 hours, but it occurs in the range of 8 to 120 hours. Analgesia lasts for 6 to 12 hours.  
A stable level is reached within 2 to 4 days. Methadone is metabolized mostly via liver 
enzymes, but also in the intestine wall via N-demethylation to inactive metabolites. The 
main enzyme responsible for methadone N-demethylation is CYP3A4 with a lesser CYP1A2 
and CYP2D6 involvement and a significant CYP2B6 role. The drug is excreted mainly via 
the alimentary tract, but also through kidneys (depending on the urine pH). In chronic renal 
disease, methadone does not accumulate; in severe renal failure, a dose reduction may be 
considered. Methadone is not eliminated in the process of hemodialysis. Methadone is more 
difficult to use than other opioids due to complicated pharmacokinetics, numerous drug 
interactions, and possible QT prolongation; therefore, it should be used by physicians 
experienced in chronic pain management (Leppert, 2009c). 
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3.7 Tapentadol 
Tapentadol chloride ([-]-[1R,2R]-3-[3-Dimethylamino-1-ethyl-2-methyl-propyl]-phenol 
hydrochloride) is an opioid with two analgesic mechanisms: agonist of µ-opioid receptors 
with 50 times less affinity than morphine, and inhibition of norepinephrine reuptake 
(Tzschentke et al., 2007). Bioavailability after oral administration is over 30%, the drug is 
metabolized to inactive metabolites through glucuronidation and excreted via kidneys 
(Kneip et al., 2008). In experimental studies tapentadol is effective in the treatment of 
neuropathic pain and in inflammatory pain. In clinical studies conducted in patients with 
low back pain, those with postoperative pain, and those with osteoarthritis, IR tapentadol at 
doses 50, 75, and 100 mg had more favorable adverse-effects profiles with less intense 
gastrointestinal adverse effects (ie, nausea, vomiting, constipation) in comparison to IR 
oxycodone at doses 10 and 15 mg. Clinical studies on tapentadol use in patients with cancer 
pain are ongoing. 
4. Conclusions 
Opioids are usually effective when administered alone or with adjuvant analgesics. The 
traditional WHO step-by-step approach should be used individually, based on the clinical 
assessment of pain type and intensity. Patients with severe pain intensity should use strong 
opioids (opioids for moderate-to-severe pain) without climbing up the analgesic ladder. 
Opioids may be combined with nonopioid analgesics and adjuvant analgesics appropriate 
for a given pain type. Understanding important attributes of commonly used opioids can 
help assist selection. 
In case of lack of efficacy of orally or transdermally administered opioids, it may be 
beneficial to change the route of administration to parenteral or intrathecal (Enting et al., 
2002). Another possibility is opioid switch that may improve analgesia and reduce adverse 
effects (Mercadante & Bruera, 2006). A good example may be patients suffering from severe 
constipation who may benefit when switching from morphine to TF (Ahmedzai & Brooks, 
1997) and from codeine or DHC to tramadol (Leppert & Majkowicz, 2010). A newer 
approach is the concomitant use of two opioids, although little evidence supports such 
procedure (Fallon & Laird, 2011). Future studies may address genetic disposition 
responsible for individual patients’ response to opioid analgesics (Lötsch et al., 2009). 
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